Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

44.00USD
18 Oct 2018
Change (% chg)

$-0.57 (-1.28%)
Prev Close
$44.57
Open
$44.33
Day's High
$44.50
Day's Low
$43.71
Volume
5,024,453
Avg. Vol
6,232,599
52-wk High
$45.81
52-wk Low
$33.20

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $214,682.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.55

Financials

  PFE.N Industry Sector
P/E (TTM): 26.26 30.92 33.69
EPS (TTM): 1.37 -- --
ROI: 6.00 14.76 14.30
ROE: 13.80 16.26 16.03

Court dismisses Australian watchdog's appeal against Pfizer ruling

Australia's competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court's decision on whether Pfizer Inc's local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor.

3:25am BST

Court dismisses Australian watchdog's appeal against Pfizer ruling

Australia's competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court's decision on whether Pfizer Inc's local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor.

3:11am BST

Court dismisses Australian watchdog's appeal against Pfizer ruling

Oct 19 Australia's competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court's decision on whether Pfizer Inc's local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor.

3:08am BST

Merck, Pfizer combo treatment meets main goals of kidney cancer trial

Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer.

18 Oct 2018

Merck, Pfizer combo treatment meets main goals of kidney cancer trial

Oct 18 Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer.

18 Oct 2018

Pfizer to cut around 2 percent of jobs through early next year

NEW YORK U.S. drugmaker Pfizer Inc plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities.

17 Oct 2018

Pfizer to cut around 2 pct of jobs through early next year

NEW YORK, Oct 17 U.S. drugmaker Pfizer Inc plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities.

17 Oct 2018

FDA approves Pfizer's drug for advanced breast cancer

The U.S. Food and Drug Administration said on Tuesday it approved Pfizer Inc's drug for an advanced form of breast cancer tied to an inherited gene mutation.

16 Oct 2018

UPDATE 1-FDA approves Pfizer's drug for advanced breast cancer

Oct 16 The U.S. Food and Drug Administration said https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm623540.htm?utm_campaign=Oncology%2010%2F16%2F18%20talazoparib&utm_medium=email&utm_source=Eloqua&elqTrackId=3d45c5bae09748aa82b26d0d48f2c15b&elq=98e4248d80d04ab2907cce369a7c5176&elqaid=5513&elqat=1&elqCampaignId=4429 on Tuesday it approved Pfizer Inc's drug for an advanced form of breast cancer tied to an inherited gene mutation.

16 Oct 2018

FDA approves Pfizer's breast cancer drug

Oct 16 The U.S. Food and Drug Administration said https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm623540.htm?utm_campaign=Oncology%2010%2F16%2F18%20talazoparib&utm_medium=email&utm_source=Eloqua&elqTrackId=3d45c5bae09748aa82b26d0d48f2c15b&elq=98e4248d80d04ab2907cce369a7c5176&elqaid=5513&elqat=1&elqCampaignId=4429 on Tuesday it approved Pfizer Inc's drug for advanced form of breast cancer.

16 Oct 2018

Competitors

Earnings vs. Estimates